This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Martelange, V. Articles by Boon, T. Search for Related Content PubMed PubMed Citation Articles by Martelange, V. Articles by Boon, T.

Identification on a Human Sarcoma of Two New Genes with Tumor-specific Expression¹

Ludwig Institute for Cancer Research, Brussels Branch, and Cellular Genetics Unit, Université Catholique de Louvain, B-1200 Brussels, Belgium

Genes MAGE, BAGE, GAGE, and LAGE-1/NY-ESO-1 code for antigens that are recognized on melanoma cells by autologous CTLs. Because the pattern of expression of these genes results in the presence of antigens on many tumors of various histological types and not on normal tissues, these antigens qualify for cancer immunotherapy. To identify new genes with tumor-specific expression, we applied a cDNA subtraction approach, i.e., representational difference analysis, to a human sarcoma cell line. We obtained two cDNA clones that appeared to be tumor specific. The corresponding genes were named SAGE and HAGE because they have the same pattern of expression as genes of the MAGE family. SAGE encodes a putative protein of 904 amino acids and shows no homology to any recorded gene. Like the MAGE-A genes, it is located in the q28 region of chromosome X. Expression of gene SAGE was observed mainly in bladder carcinoma, lung carcinoma, and head and neck carcinoma but not in normal tissues, with the exception of testis. Gene HAGE, which is located on chromosome 6, encodes a putative protein of 648 amino acids. This protein is a new member of the DEAD-box family of ATP-dependent RNA helicases. Gene HAGE is expressed in many tumors of various histological types at a level that is 100-fold higher than the level observed in normal tissues except testis. Because of this tumor-specific expression, genes SAGE and HAGE ought to encode antigens that could be useful for antitumoral therapeutic vaccination.

This article has been cited by other articles:

				T. Yokoe, F. Tanaka, K. Mimori, H. Inoue, T. Ohmachi, M. Kusunoki, and M. Mori Efficient Identification of a Novel Cancer/Testis Antigen for Immunotherapy Using Three-Step Microarray Analysis Cancer Res., February 15, 2008; 68(4): 1074 - 1082. [Abstract] [Full Text] [PDF]

				J. Roman-Gomez, A. Jimenez-Velasco, X. Agirre, J. A. Castillejo, G. Navarro, E. San Jose-Eneriz, L. Garate, L. Cordeu, F. Cervantes, F. Prosper, et al. Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia Haematologica, February 1, 2007; 92(2): 153 - 162. [Abstract] [Full Text] [PDF]

				P. Linder Dead-box proteins: a family affair--active and passive players in RNP-remodeling Nucleic Acids Res., September 10, 2006; 34(15): 4168 - 4180. [Abstract] [Full Text] [PDF]

				H.-J. Heidebrecht, A. Claviez, M. L. Kruse, M. Pollmann, F. Buck, S. Harder, M. Tiemann, W. Dorffel, and R. Parwaresch Characterization and Expression of CT45 in Hodgkin's Lymphoma. Clin. Cancer Res., August 15, 2006; 12(16): 4804 - 4811. [Abstract] [Full Text] [PDF]

				Y. Miyahara, H. Naota, L. Wang, A. Hiasa, M. Goto, M. Watanabe, S. Kitano, S. Okumura, T. Takemitsu, A. Yuta, et al. Determination of Cellularly Processed HLA-A2402-Restricted Novel CTL Epitopes Derived from Two Cancer Germ Line Genes, MAGE-A4 and SAGE Clin. Cancer Res., August 1, 2005; 11(15): 5581 - 5589. [Abstract] [Full Text] [PDF]

				Y.-T. Chen, M. J. Scanlan, C. A. Venditti, R. Chua, G. Theiler, B. J. Stevenson, C. Iseli, A. O. Gure, T. Vasicek, R. L. Strausberg, et al. Identification of cancer/testis-antigen genes by massively parallel signature sequencing PNAS, May 31, 2005; 102(22): 7940 - 7945. [Abstract] [Full Text] [PDF]

				H. Takedatsu, S. Shichijo, K. Katagiri, H. Sawamizu, M. Sata, and K. Itoh Identification of Peptide Vaccine Candidates Sharing among HLA-A3+, -A11+, -A31+, and -A33+ Cancer Patients Clin. Cancer Res., February 1, 2004; 10(3): 1112 - 1120. [Abstract] [Full Text] [PDF]

				H Nagel, R Laskawi, H Eiffert, and T Schlott Analysis of the tumour suppressor genes, FHIT and WT-1, and the tumour rejection genes, BAGE, GAGE-1/2, HAGE, MAGE-1, and MAGE-3, in benign and malignant neoplasms of the salivary glands Mol. Pathol., August 1, 2003; 56(4): 226 - 231. [Abstract] [Full Text] [PDF]

				B. Zhu, Z. Chen, X. Cheng, Z. Lin, J. Guo, Z. Jia, L. Zou, Z. Wang, Y. Hu, D. Wang, et al. Identification of HLA-A*0201-restricted Cytotoxic T Lymphocyte Epitope from TRAG-3 Antigen Clin. Cancer Res., May 1, 2003; 9(5): 1850 - 1857. [Abstract] [Full Text] [PDF]

				S.-Y. Lee, Y. Obata, M. Yoshida, E. Stockert, B. Williamson, A. A. Jungbluth, Y.-T. Chen, L. J. Old, and M. J. Scanlan Immunomic analysis of human sarcoma PNAS, March 4, 2003; 100(5): 2651 - 2656. [Abstract] [Full Text] [PDF]

				M. Koslowski, O. Tureci, C. Bell, P. Krause, H.-A. Lehr, J. Brunner, G. Seitz, F. O. Nestle, C. Huber, and U. Sahin Multiple Splice Variants of Lactate Dehydrogenase C Selectively Expressed in Human Cancer , Cancer Res., November 15, 2002; 62(22): 6750 - 6755. [Abstract] [Full Text] [PDF]

				J. F Costello and C. Plass Methylation matters J. Med. Genet., May 1, 2001; 38(5): 285 - 303. [Abstract] [Full Text]